Request Clinical Starter Kits for Your Patients Today! Request Now

Are you a clinician?

This is a clinician-only website.
By entering, you acknowledge that you're a clinician.

ENDUR-ACIN® improves blood lipids and transport proteins in familial hypercholesterolemia, study shows


  • ENDUR-ACIN® improves blood lipids in patients with Types IIa and IIb hyperlipoproteinemias
  • Improvements in lipid transport proteins apo-A1 and apo-B also seen
  • Treatment reported to be well tolerated by patients.


This clinical study was designed to assess the effects and tolerance of ENDUR-ACIN® wax matrix niacin in the treatment of dyslipidemia in 31 patients with Types IIa and IIb hyperlipoproteinemias. The study was a 6-month blinded, crossover study.

Results indicate ENDUR-ACIN® treatment reduced total cholesterol by 9-13%, reduced low-density lipoprotein (LDL) cholesterol by 12-22%, and increased high-density lipoprotein (HDL) cholesterol by 12-15%. Moreover, ENDUR-ACIN® treatment resulted in improvements in blood lipid transport proteins, including a 12-16% increase in apoprotein AI and 29% decrease in apoprotein B. Treatment was reported to be well tolerated by patients.

These findings indicate ENDUR-ACIN® has clinical value in treating familial hypercholesterolemia.


Oganov RG, Kiseleva NG, Aronov DM, et al. The use of Enduracin – a prolonged-action form of nicotinic acid – in correcting atherogenic dyslipidemias (in Russian; English abstract). Kardiologiia. 1993;33(10):54-9, 6.

PMID: 8139175